Prognostic Role of ABO Blood Type in Operable Esophageal Cancer: Analysis of 2179 Southern Chinese Patients.

ABO blood group esophageal cancer large cohort prognostic factor survival

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 22 07 2020
accepted: 17 11 2020
entrez: 4 1 2021
pubmed: 5 1 2021
medline: 5 1 2021
Statut: epublish

Résumé

The prognostic value of ABO blood types is not well clarified for esophageal carcinoma (EC). This study attempted to elucidate the associations between different ABO blood types and disease-free survival (DFS) and overall survival (OS) of EC. This study was a retrospective review of the records of 2179 patients with EC who received surgery from December 2000 to December 2008. The prognostic impact of ABO blood group on DFS and OS were estimated using the Kaplan-Meier method and cox proportional hazard models. Univariate analyses found significant differences in DFS and OS among the four blood types. Multivariate analyses showed ABO blood type independently predicted DFS ( The results demonstrate that ABO blood group is an independent prognostic factor of survival, and that type B predicts a favorable prognosis, whereas type O predicts an unfavorable prognosis for survival in patients with EC, especially those with ESCC.

Sections du résumé

BACKGROUND BACKGROUND
The prognostic value of ABO blood types is not well clarified for esophageal carcinoma (EC). This study attempted to elucidate the associations between different ABO blood types and disease-free survival (DFS) and overall survival (OS) of EC.
METHODS METHODS
This study was a retrospective review of the records of 2179 patients with EC who received surgery from December 2000 to December 2008. The prognostic impact of ABO blood group on DFS and OS were estimated using the Kaplan-Meier method and cox proportional hazard models.
RESULTS RESULTS
Univariate analyses found significant differences in DFS and OS among the four blood types. Multivariate analyses showed ABO blood type independently predicted DFS (
CONCLUSIONS CONCLUSIONS
The results demonstrate that ABO blood group is an independent prognostic factor of survival, and that type B predicts a favorable prognosis, whereas type O predicts an unfavorable prognosis for survival in patients with EC, especially those with ESCC.

Identifiants

pubmed: 33392080
doi: 10.3389/fonc.2020.586084
pmc: PMC7775654
doi:

Types de publication

Journal Article

Langues

eng

Pagination

586084

Informations de copyright

Copyright © 2020 Zhang, Jia, Cai, Yang, Liao, Liu, Wen, Luo and Cheng.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cancer Causes Control. 2011 Apr;22(4):649-57
pubmed: 21321789
PLoS Genet. 2008 Jul 04;4(7):e1000118
pubmed: 18604267
World J Gastroenterol. 2001 Oct;7(5):657-61
pubmed: 11819849
PLoS One. 2015 Apr 13;10(4):e0123246
pubmed: 25874561
BMC Surg. 2015 Sep 29;15:106
pubmed: 26420728
Nature. 1983 Jun 9-15;303(5917):522-4
pubmed: 6855897
Dis Esophagus. 2004;17(2):146-9
pubmed: 15230728
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Onco Targets Ther. 2015 Apr 23;8:947-53
pubmed: 25960667
Cancer Sci. 2014 Dec;105(12):1638-46
pubmed: 25287715
Br J Cancer. 2013 Oct 29;109(9):2462-6
pubmed: 24022193
Br J Cancer. 2014 Jul 8;111(1):174-80
pubmed: 24901236
Cancer Causes Control. 2014 Oct;25(10):1369-77
pubmed: 25064033
J Surg Res. 2016 Mar;201(1):188-95
pubmed: 26850201
Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1958-67
pubmed: 19729612
BMC Cancer. 2012 Jul 28;12:319
pubmed: 22838843
PLoS Genet. 2008 May 09;4(5):e1000072
pubmed: 18464913
World J Surg. 2003 May;27(5):571-9
pubmed: 12715226
Front Oncol. 2018 Oct 23;8:461
pubmed: 30406028
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
APMIS. 2001 Jan;109(1):9-31
pubmed: 11297197
Hum Mol Genet. 2010 May 1;19(9):1863-72
pubmed: 20167578
Surg Today. 2017 Aug;47(8):959-965
pubmed: 28028639
N Engl J Med. 2003 Dec 4;349(23):2241-52
pubmed: 14657432
Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1028-1035
pubmed: 30872314
Biomed Res Int. 2014;2014:286810
pubmed: 25054136
Br J Cancer. 2013 Nov 26;109(11):2894-903
pubmed: 24201750
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
World J Gastroenterol. 2012 Feb 14;18(6):563-9
pubmed: 22363124

Auteurs

Shuishen Zhang (S)

Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Minghan Jia (M)

Department of Breast Cancer, Guangdong Provincial People's Hospital Cancer Center, Guangdong Academy of Medical Sciences, Guangzhou, China.

Xiaoli Cai (X)

Department of Medical Ultrasonics, First Affiliated Hospital of Jinan University, Guangzhou, China.

Weixiong Yang (W)

Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Shufen Liao (S)

Operating room of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Zhenguo Liu (Z)

Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Jing Wen (J)

Guangdong Esophageal Cancer Institute, Guangzhou, China.
Department of Thoracic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.

Kongjia Luo (K)

Guangdong Esophageal Cancer Institute, Guangzhou, China.
Department of Thoracic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Chao Cheng (C)

Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Classifications MeSH